Cartesian Therapeutics, Inc. is a clinical-stage company. Co. is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Co. is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. We show 6 historical shares outstanding datapoints in our RNAC shares outstanding history coverage, used to compute RNAC market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RNAC market cap history over the course of time is important for investors
interested in comparing RNAC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RNAC versus a peer is one thing; comparing
RNAC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RNAC can fluctuate over the course of history.
With this page we aim to empower investors researching RNAC by allowing them to research the RNAC market cap history. |
Free RNAC Email Alerts:
Video: The Importance of Market Cap
